Boehringer Ingelheim Corporation

Type: Company
Name: Boehringer Ingelheim Corporation
First reported 16 hours ago - Updated 8 hours ago - 1 reports

Analysis of Phase III Trials Examines the Impact of Nintedanib on Lung Function Decline

– A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS™ trials, presented today at the European Respiratory Society International Congress (ERS) evaluated the impact of the investigational drug nintedanib ... [Published Drugs.com - 16 hours ago]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

ESC Hot Line: Data Reports NVAF Patients Taking -2-

expected to affect dabigatran anticoagulant activity. Consideradministration of platelet concentrates where thrombocytopenia is presentor long-acting antiplatelet drugs have been used.Thromboembolic and Bleeding Events in Patients with Prosthetic Heart ... [Published Scottrade - Sep 02 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors

CHICAGO, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics ( Nasdaq:DRTX ) today announced that Wendy Yarno and Marty Carroll were added to its Board of Directors at a quarterly meeting of the Board held today. The Company also announced the departure ... [Published CEOWorld Magazine - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

INSIDE INDIANA BUSINESS: New Indy Airport leader looks to future

Indianapolis Airport Authority Executive Director Mario Rodriguez, who has been on the job since June, says major airline mergers have led the airport to increase focus on growing carriers such as Jet Blue Airways and Virgin America.Council OKs Multiple ... [Published NWI Times - Aug 26 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Lilly Diabetes Treatment Now Available

A type 2 diabetes treatment developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Boehringer Ingelheim Corp. is now available by prescription. The U.S. Food and Drug Administration approved Jardiance earlier this month for use in improving ... [Published Inside INdiana Business - Aug 26 2014]
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol

olodaterol and tiotropiumTreatment for Chronic Obstructive Pulmonary Disease NDA for Tiotropium Plus Olodaterol Accepted for Review by FDA RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration ... [Published Drugs.com - Aug 23 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Eli Lilly Gets Tentative FDA Approval For Diabetes Drug

Eli Lilly and Boehringer Ingelheim’s diabetes drug gains tentative FDA approval which is still subject to the decision about the patent lawsuit filed by SanofiPage 1 of 2Click Ticker to See live coverageEli Lilly and Co ( LLY ) announced on Monday, that ... [Published Bidness Etc - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

INSIDE INDIANA BUSINESS: Study suggests energy effort paying off

A report commissioned by the Indiana Utility Regulatory Commission suggests a statewide energy efficiency initiative's efforts have returned as much as $3 in benefits for each $1 spent from 2012-13. Energizing Indiana's programs are set to wrap up by ... [Published NWI Times - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Lilly Diabetes Drug Moves Forward

A diabetes treatment being developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Boehringer Ingelheim Corp. in Connecticut has received tentative approval from the U.S. Food and Drug Administration. Final approval for Basaglar is contingent ... [Published Inside INdiana Business - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Boehringer Ingelheim Corporation Goes On A Hiring Freeze And Plans To Chop Jobs

Boehringer Ingelheim is axing jobs but others are hiring too! Check it out! (Isn't it tempting?)Germany's Boehringer Ingelheim has implemented a hiring freeze and plans to reduce its headcount in its home market in a bid to reduce costs.The news was revealed ... [Published BioSpace - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

FDA approves ]ardiance® tablets for adults with type 2 diabetes

RIDGEFIELD, Conn., and INDIANAPOLIS— (BIPI) and have announced that the approved Jardiance· (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). Jardiance ... [Published Drug Discovery News - Aug 11 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

US FDA approves Jardiance tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced the US Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose ... [Published PharmaBiz - Aug 05 2014]

Quotes

...executives with extensive leadership experience at large pharmaceutical companies," said Richard De Schutter, Durata's Chairman of the Board. "We would also like to thank Ron for his many contributions and his commitment to Durata."
"The FDA's acceptance of our application for the fixed-dose combination of tiotropium and olodaterol is an important milestone for our company, and it reinforces Boehringer Ingelheim's steadfast commitment to COPD" said Sabine Luik, M D , senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc
"Because of the combined diabetes, development and commercialization experience of Lilly and Boehringer Ingelheim, we are confident that Basaglar, upon final approval, will become a valuable treatment choice for people who need a basal insulin to manage their type 1 or type 2 diabetes" said Christophe Arbet-Engels, M D , Ph D , vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals...
...RESPIMAT in the U S ," said Sabine Luik, M D , senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "At Boehringer Ingelheim, we have been committed to discovering and developing new treatments to help people affected by COPD for several decades. If approved, tiotropium RESPIMAT would build upon our heritage in treating respiratory diseases by equipping healthcare providers and their patients with an important new treatment option."

More Content

All (25) | News (24) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Analysis of Phase III Trials Examines the Impac... [Published Drugs.com - 16 hours ago]
Durata Therapeutics Names Wendy Yarno and J. Ma... [Published OrbiMed Advisors - Sep 05 2014]
ESC Hot Line: Data Reports NVAF Patients Taking... [Published Scottrade - Sep 02 2014]
Durata Therapeutics Names Wendy Yarno and J. Ma... [Published CEOWorld Magazine - Aug 26 2014]
INSIDE INDIANA BUSINESS: New Indy Airport leade... [Published NWI Times - Aug 26 2014]
Lilly Diabetes Treatment Now Available [Published Inside INdiana Business - Aug 26 2014]
Pradaxa® (dabigatran etexilate mesylate) Data t... [Published Insurance News Net - Aug 25 2014]
Boehringer Ingelheim Announces U.S. Filing for ... [Published Drugs.com - Aug 23 2014]
INSIDE INDIANA BUSINESS: Study suggests energy ... [Published NWI Times - Aug 19 2014]
Lilly Diabetes Drug Moves Forward [Published Inside INdiana Business - Aug 19 2014]
Boehringer Ingelheim Announces U.S. Filing for ... [Published CBS Detroit - Aug 19 2014]
Eli Lilly Gets Tentative FDA Approval For Diabe... [Published Bidness Etc - Aug 19 2014]
FDA Grants Tentative Approval for Lilly and Boe... [Published PredictWallStreet - Aug 18 2014]
Veterinary Health Markets [Published CW Atlanta - Aug 18 2014]
FDA Advisory Committee Recommends Approval of T... [Published CBS Detroit - Aug 14 2014]
Boehringer Ingelheim Corporation Goes On A Hiri... [Published BioSpace - Aug 12 2014]
FDA approves ]ardiance® tablets for adults with... [Published Drug Discovery News - Aug 11 2014]
US FDA approves Jardiance tablets for adults wi... [Published PharmaBiz - Aug 05 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
Boehringer Ingelheim, Lilly resubmit SGLT2 inhi... [Published PharmaBiz - Jun 19 2014]
Two phase III trials of empagliflozin/linaglipt... [Published PharmaBiz - Jun 17 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
EU recommends approval of empagliflozin to redu... [Published PharmaBiz - Mar 24 2014]
CEO Cancer Gold Standard accreditation awarded ... [Published BioPortfolio - Dec 13 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.